[Stereotactic body radiotherapy as "first-line treatment" for oligometastatic renal cell cancer]

[Article in German]

Affiliations

Comment

[Article in German]

Matthias Guckenberger. Strahlenther Onkol. 2022 May.

. 2022 May;198(5):497-499.

doi: 10.1007/s00066-022-01920-7. Epub 2022 Mar 12.

¹ Department of Radiation Oncology, Universitäts-Spital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz. Matthias.Guckenberger@usz.ch.

No abstract available

Comment on

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Tang C, et al. Lancet Oncol. 2021 Dec;22(12):1732-1739. doi: 10.1016/S1470-2045(21)00528-3. Epub 2021 Oct 28. Lancet Oncol. 2021. PMID: 34717797 Free PMC article. Clinical Trial.

1. Siva S et al (2018) Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK): pooled analysis of SABR for primary RCC. Cancer 124:934–942 - DOI
1. Hoerner-Rieber J et al (2017) Stereotactic body radiotherapy (SBRT) for pulmonary metastases from renal cell carcinoma‑a multicenter analysis of the German working group “Stereotactic Radiotherapy”. J Thorac Dis 9:4512–4522 - DOI
1. Kroeze SGC et al (2021) Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int 127:703–711 - DOI
1. Sheehan JP, Sun M‑H, Kondziolka D, Flickinger J, Lunsford LD (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342–349 - DOI
1. Palma DA et al (2019) Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.6993 - DOI - PubMed - PMC